NEW YORK, August 18, 2016 – Arsenal Capital Partners, a New York based private equity firm, announced today that its portfolio company WIRB-Copernicus Group® (WCG™), has completed a recapitalization in which Arsenal Capital Partners led an investment group, including Arsenal Capital Fund IV, MSD Capital, L.P. and other leading institutional investors, to provide WCG with additional capital to continue its successful growth.
BioIVT is the leading provider of biological and in vitro products to the pharmaceutical, diagnostic, and biotechnology organizations. BioIVT’s products are used in drug discovery, biomarker, toxicology, bioanalytical and ADME research. The company’s products and value added services enable its clients to significantly reduce the time and expense of bringing new drugs and diagnostics to market.
Arsenal Capital Partners is a specialized private equity firm that invests in the U.S. middle market with a narrow and deep focus in two sectors, Specialty Industrials and Healthcare. Our philosophy is to partner with talented management teams, provide them with access to world-class operating resources and patient capital, and develop positive, open and constructive relationships that foster long-term value creation.